InterCure CEO Alex Rabinovitch Purchases Over 420,000 Shares of Company Stock in The Open Market

Rhea-AI Summary

InterCure Ltd (NASDAQ: INCR) announced that CEO Alexander Rabinovitch bought 423,501 shares of the company's common stock in September 2021 at an average price of USD $7.03 per share, totaling USD $2,975,730. These purchases were made on NASDAQ and the Tel Aviv Stock Exchange. InterCure, operating as Canndoc, is Israel's largest licensed cannabis producer and one of the fastest-growing cannabis companies outside North America, leveraging a high-margin, vertically integrated model and robust distribution network.

Positive

• CEO purchase of 423,501 shares indicates strong insider confidence.
• InterCure is the largest licensed cannabis producer in Israel.
• The company operates with a high-margin vertically integrated model.

Negative

• None.

NEW YORK, TORONTO and HERZLIYA, Israel, Oct. 12, 2021 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the “Company”) today announced that CEO Alexander Rabinovitch purchased, throughout the month of September 2021, a total of 423,501 shares of the Company’s common stock.

Mr. Rabinovitch purchased the shares by buying 423,501 shares in the open market at an average price of USD$7.03 per share (CAD $8.95 or NIS 22.69). The shares were purchased partially on the NASDAQ and in part on the Tel Aviv Stock Exchange, for a total investment in the Company of USD$2,975,730 (CAD $3,790,238 per share or NIS 9,608,631).

About InterCure (dba Canndoc)

InterCure (dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel's largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of North America.

For more information, visit: http://www.intercure.co.

To be added to InterCure’s email distribution list, please email InterCure@kcsa.com with “InterCure” in the subject.

Contact:

InterCure Ltd.
Amos Cohen, Chief Financial Officer
amos@canndoc-pharma.com

KCSA Strategic Communications
Investor and Media Relations
InterCure@kcsa.com

 

FAQ

What did CEO Alexander Rabinovitch do in September 2021 regarding InterCure?

In September 2021, CEO Alexander Rabinovitch purchased 423,501 shares of InterCure's stock at an average price of USD $7.03.

What is the total investment made by the CEO in InterCure?

The total investment made by CEO Alexander Rabinovitch in InterCure was USD $2,975,730.

How is InterCure Ltd positioned in the cannabis market?

InterCure Ltd is the largest licensed cannabis producer in Israel and one of the fastest-growing cannabis companies outside North America.

What stock exchange does InterCure Ltd trade on?

InterCure Ltd trades on NASDAQ, TSX, and the Tel Aviv Stock Exchange with the stock symbol INCR.

What does InterCure's business model entail?

InterCure operates a high-margin vertically integrated 'seed-to-sale' business model.